论文部分内容阅读
蛋白酶体抑制剂硼替佐米,在治疗初治性和复发性/难治性多发性骨髓瘤患者时都已显示出相当高的疗效。硼替佐米能作用NF-κB受体配体/骨保护素(RANKL/OPG)系统与Wnt信号转导途径而调节破骨细胞活性与成骨细胞骨功能协调平衡,由此达到治疗骨髓瘤性骨病目的。
The proteasome inhibitor bortezomib has shown considerable efficacy in the treatment of both debilitating and refractory multiple myeloma patients. Bortezomib mediates the balance of osteoclast activity and osteoblast function by acting on the NF-κB receptor ligand / osteoprotegerin (RANKL / OPG) system and the Wnt signaling pathway, thereby achieving the goal of treating myeloma The purpose of bone disease.